Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 12.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 972,575 shares of the company’s stock after purchasing an additional 104,892 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Replimune Group were worth $11,778,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Replimune Group by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock valued at $2,733,000 after buying an additional 8,074 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Replimune Group by 14.7% in the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after acquiring an additional 3,374 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after acquiring an additional 3,177 shares during the period. Rhumbline Advisers increased its stake in shares of Replimune Group by 8.3% during the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock valued at $1,156,000 after acquiring an additional 7,317 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Replimune Group by 260.8% during the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company’s stock worth $523,000 after purchasing an additional 31,231 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $7.41 on Wednesday. The company has a market capitalization of $570.68 million, a PE ratio of -2.41 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a fifty day moving average of $9.27 and a 200-day moving average of $11.45. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, equities analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.